| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | C6 |
| Uniprot No | P13671 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-934aa |
| 氨基酸序列 | FCDHYAWTQWTSCSKTCNSGTQSRHRQIVVDKYYQENFCEQICSKQETRE CNWQRCPINCLLGDFGPWSDCDPCIEKQSKVRSVLRPSQFGGQPCTEPLV AFQPCIPSKLCKIEEADCKNKFRCDSGRCIARKLECNGENDCGDNSDERD CGRTKAVCTRKYNPIPSVQLMGNGFHFLAGEPRGEVLDNSFTGGICKTVK SSRTSNPYRVPANLENVGFEVQTAEDDLKTDFYKDLTSLGHNENQQGSFS SQGGSSFSVPIFYSSKRSENINHNSAFKQAIQASHKKDSSFIRIHKVMKV LNFTTKAKDLHLSDVFLKALNHLPLEYNSALYSRIFDDFGTHYFTSGSLG GVYDLLYQFSSEELKNSGLTEEEAKHCVRIETKKRVLFAKKTKVEHRCTT NKLSEKHEGSFIQGAEKSISLIRGGRSEYGAALAWEKGSSGLEEKTFSEW LESVKENPAVIDFELAPIVDLVRNIPCAVTKRNNLRKALQEYAAKFDPCQ CAPCPNNGRPTLSGTECLCVCQSGTYGENCEKQSPDYKSNAVDGQWGCWS SWSTCDATYKRSRTRECNNPAPQRGGKRCEGEKRQEEDCTFSIMENNGQP CINDDEEMKEVDLPEIEADSGCPQPVPPENGFIRNEKQLYLVGEDVEISC LTGFETVGYQYFRCLPDGTWRQGDVECQRTECIKPVVQEVLTITPFQRLY RIGESIELTCPKGFVVAGPSRYTCQGNSWTPPISNSLTCEKDTLTKLKGH CQLGQKQSGSECICMSPEEDCSHHSEDLCVFDTDSNDYFTSPACKFLAEK CLNNQQLHFLHIGSCQDGRQLEWGLERTRLSSNSTKKESCGYDTCYDWEK CSASTSKCVCLLPPQCFKGGNQLYCVKMGSSTSEKTLNICEVGTIRCANR KMEILHPGKCLA |
| 预测分子量 | 126 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于C6重组蛋白的模拟参考文献示例(注：以下内容为虚构，仅用于演示格式)：
---
1. **文献名称**：Functional Characterization of Recombinant Human C6 in Complement-Mediated Hemolysis
**作者**：Lee S, et al.
**摘要**：研究通过哺乳动物表达系统成功制备重组人C6蛋白，证实其可恢复C6缺陷血清的溶血活性，揭示了C6在补体终末通路中与C5b的结合特异性。
2. **文献名称**：Structural Insights into Recombinant C6 for Targeted Drug Design
**作者**：Garcia M, et al.
**摘要**：利用冷冻电镜解析重组C6蛋白的构象变化，发现其与C5b-7复合物结合的动态机制，为开发补体过度激活相关疾病的抑制剂提供结构依据。
3. **文献名称**：Recombinant C6 as a Therapeutic Agent in Experimental Sepsis
**作者**：Chen H, et al.
**摘要**：动物实验表明，补充重组C6蛋白可增强宿主对细菌膜攻击复合物的形成能力，显著降低脓毒症模型的死亡率，提示其作为免疫增强剂的潜力。
4. **文献名称**：High-Yield Production of Recombinant C6 in Insect Cells and Its Autoimmune Disease Applications
**作者**：Wang Q, et al.
**摘要**：通过杆状病毒-昆虫细胞系统高效表达功能性C6蛋白，并验证其用于检测补体活性异常导致的自身免疫性疾病(如PNH)的诊断价值。
---
以上摘要涵盖C6重组蛋白的功能验证、结构研究、治疗应用及生产优化，符合基础研究和临床转化的多方向需求。如需真实文献，建议通过PubMed或Web of Science以“recombinant C6 protein”为关键词检索。
C6 recombinant protein is a key component derived from the complement system, an essential part of innate immunity. The complement system comprises a cascade of proteins that mediate immune responses, including pathogen elimination and inflammation. Complement component C6. a ~120 kDa glycoprotein, plays a critical role in the formation of the membrane attack complex (MAC). The MAC, composed of terminal complement proteins (C5b, C6. C7. C8. and C9), forms pores on pathogen membranes, leading to cell lysis. C6 binds to C5b during MAC assembly, stabilizing the complex and enabling subsequent incorporation of C7. C8. and C9.
Recombinant C6 is produced using genetic engineering techniques, typically in mammalian expression systems (e.g., CHO or HEK293 cells) to ensure proper post-translational modifications. Its production enables controlled study of MAC formation and regulation, bypassing variability in native protein purification. Researchers use recombinant C6 to investigate complement-mediated pathologies, such as hemolytic disorders, neurodegenerative diseases, and autoimmune conditions. It also serves as a tool to develop therapeutic inhibitors targeting MAC-driven inflammation, particularly in diseases like paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD).
Additionally, recombinant C6 aids in diagnostics, helping detect complement activation abnormalities. Its availability accelerates drug discovery, as screening assays can evaluate compounds that modulate MAC activity. As dysregulated complement activation is implicated in numerous diseases, recombinant C6 remains vital for both basic research and clinical applications, offering insights into MAC’s dual role in host defense and tissue damage. Commercial suppliers provide purified C6 protein, often with validated functional activity, supporting standardized research across laboratories.
×
